Physician profile
Elizabeth Kiselak
NPI 1912296195
$1,803.49
in general payments reported to CMS, 2019-2025
12 companies · $18.43 in 2025
The $18.43 reported for 2025 was less than what a typical Trauma Surgery provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $166 · 2021: $209 · 2023: $232 · 2024: $1,057 · 2025: $18.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $916 · Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $916.49 |
| Food and Beverage | $390.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,060.05 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $142.46 | 2023 | Advantagerib |
| Haemonetics Corporation | $142.27 | 2021-2025 | Teg6s Hemostasis System |
| Smith+Nephew, INC. | $122.32 | 2019-2021 | |
| Ethicon US, LLC | $112.40 | 2019-2021 | |
| Polarityte, INC. | $77.37 | 2020-2021 | |
| Atricure, INC. | $50.16 | 2019 | |
| Integra Lifesciences Corporation | $29.70 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kci USA, INC. | $21.17 | 2021 | |
| Portola Pharmaceuticals, LLC | $16.65 | 2020 | |
| Acell, INC. | $15.32 | 2020 | |
| Shire North American Group INC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Kiselak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.